FIMP1

Summary

FIMP1 (fertilization-influencing membrane protein 1, HGNC:26346) is a protein-coding gene on chromosome 16p11.2, encoding Fertilization-influencing membrane protein (Q96LL3). May play a role in sperm-oocyte fusion during fertilization.

Predicted to be involved in fusion of sperm to egg plasma membrane involved in single fertilization. Predicted to be located in plasma membrane.

Source: NCBI Gene 146378 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 31 total — 3 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 2
• MANE Select transcript: NM_001109659

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26346
Approved symbol	FIMP1
Name	fertilization-influencing membrane protein 1
Location	16p11.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25404, FIMP
Ensembl gene	ENSG00000167194
Ensembl biotype	protein_coding
OMIM	618911
Entrez	146378

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 nonsense_mediated_decay

ENST00000300575, ENST00000561910, ENST00000567847, ENST00000569198, ENST00000681219

RefSeq mRNA: 3 — MANE Select: NM_001109659 NM_001109659, NM_001109660, NM_001353379

CCDS: CCDS42146, CCDS92135

Canonical transcript exons

ENST00000681219 — 4 exons

Exon	Start	End
ENSE00003524650	30023999	30024086
ENSE00003911254	30024206	30024704
ENSE00003912791	30023198	30023404
ENSE00003912794	30023727	30023885

Expression profiles

Bgee: expression breadth ubiquitous, 114 present calls, max score 90.08.

Top tissues by expression

224 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	90.08	gold quality
left testis	UBERON:0004533	90.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.91	gold quality
testis	UBERON:0000473	85.99	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.58	gold quality
cerebellar hemisphere	UBERON:0002245	83.04	gold quality
cerebellar cortex	UBERON:0002129	82.86	gold quality
cerebellum	UBERON:0002037	80.94	gold quality
pituitary gland	UBERON:0000007	74.10	gold quality
adenohypophysis	UBERON:0002196	73.58	gold quality
ganglionic eminence	UBERON:0004023	71.96	gold quality
endothelial cell	CL:0000115	70.28	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	69.47	gold quality
right frontal lobe	UBERON:0002810	66.59	gold quality
sperm	CL:0000019	64.86	silver quality
primary visual cortex	UBERON:0002436	64.59	gold quality
cortical plate	UBERON:0005343	64.46	gold quality
Brodmann (1909) area 9	UBERON:0013540	64.18	gold quality
occipital lobe	UBERON:0002021	62.72	gold quality
prefrontal cortex	UBERON:0000451	62.65	gold quality
neocortex	UBERON:0001950	60.88	gold quality
anterior cingulate cortex	UBERON:0009835	60.82	gold quality
frontal cortex	UBERON:0001870	60.81	gold quality
brain	UBERON:0000955	60.08	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	59.57	gold quality
hypothalamus	UBERON:0001898	58.47	gold quality
superior surface of tongue	UBERON:0007371	58.30	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	58.12	gold quality
cerebral cortex	UBERON:0000956	57.70	gold quality
dorsal root ganglion	UBERON:0000044	57.63	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.48

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting FIMP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-4297	98.77	66.95	2013
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-4709-5P	98.51	67.25	1335
HSA-MIR-7158-3P	98.46	66.45	728
HSA-MIR-4665-5P	97.91	67.69	1536
HSA-MIR-6799-3P	97.35	65.60	1302
HSA-MIR-3907	96.76	65.04	662

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	4930451I11Rik	ENSMUSG00000045989
rattus_norvegicus		ENSRNOG00000090560

Protein

Protein identifiers

Fertilization-influencing membrane protein — Q96LL3 (reviewed: Q96LL3)

All UniProt accessions (4): H3BMV0, H3BSP6, H3BVC3, Q96LL3

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in sperm-oocyte fusion during fertilization.

Subcellular location. Cell membrane.

Tissue specificity. Testis-specific.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96LL3-1	1	yes
Q96LL3-2	2

RefSeq proteins (3): NP_001103129, NP_001103130, NP_001340308 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR038813	FIMP	Family

Pfam: PF17672

UniProt features (3 total): chain 1, transmembrane region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96LL3-F1	65.84	0.14

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 28 (showing top): GOBP_SINGLE_FERTILIZATION, GOBP_MEMBRANE_FUSION, GOBP_PLASMA_MEMBRANE_ORGANIZATION, chr16p11, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, GOBP_PLASMA_MEMBRANE_FUSION, GOBP_MEMBRANE_ORGANIZATION, GOBP_FERTILIZATION, MIKKELSEN_IPS_LCP_WITH_H3K4ME3, MIKKELSEN_ES_LCP_WITH_H3K4ME3, MARTENS_TRETINOIN_RESPONSE_UP, ZNF664_TARGET_GENES, MIR3934_3P, SMN1_SMN2_TARGET_GENES

GO Biological Process (3): fusion of sperm to egg plasma membrane involved in single fertilization (GO:0007342), fertilization (GO:0009566), single fertilization (GO:0007338)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
single fertilization	1
cellular process involved in reproduction in multicellular organism	1
sexual reproduction	1
reproductive process	1
fertilization	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

268 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FIMP1	C16orf54	Q6UWD8	692
FIMP1	ASPHD1	Q5U4P2	680
FIMP1	DOC2A	Q14183	626
FIMP1	YPEL3	P61236	607
FIMP1	HIRIP3	Q9BW71	602
FIMP1	KCTD13	Q8WZ19	598
FIMP1	SEZ6L2	Q6UXD5	592
FIMP1	TMEM219	Q86XT9	592
FIMP1	PAGR1	Q9BTK6	583
FIMP1	INO80E	Q8NBZ0	571
FIMP1	TLCD3B	Q71RH2	555
FIMP1	PRRT2	Q7Z6L0	510
FIMP1	STATH	P02808	507
FIMP1	TAOK2	Q9UL54	506
FIMP1	KIF22	Q14807	503

IntAct

32 interactions, top by confidence:

A	B	Type	Score
SEC22A	FIMP	psi-mi:“MI:0915”(physical association)	0.560
FIMP	MYADM	psi-mi:“MI:0915”(physical association)	0.560
STATH	FIMP	psi-mi:“MI:0915”(physical association)	0.560
RETREG3	FIMP	psi-mi:“MI:0915”(physical association)	0.560
PGA4	FIMP	psi-mi:“MI:0915”(physical association)	0.560
CXCL9	FIMP	psi-mi:“MI:0915”(physical association)	0.560
LRP10	FIMP	psi-mi:“MI:0915”(physical association)	0.560
TMEM35A	FIMP	psi-mi:“MI:0915”(physical association)	0.560
PLPP6	FIMP	psi-mi:“MI:0915”(physical association)	0.560
NSG1	FIMP	psi-mi:“MI:0915”(physical association)	0.560
FIMP	B4GALT5	psi-mi:“MI:0914”(association)	0.350
SEC22A	FIMP	psi-mi:“MI:0915”(physical association)	0.000
FIMP	RETREG3	psi-mi:“MI:0915”(physical association)	0.000
PGA4	FIMP	psi-mi:“MI:0915”(physical association)	0.000
CXCL9	FIMP	psi-mi:“MI:0915”(physical association)	0.000
LRP10	FIMP	psi-mi:“MI:0915”(physical association)	0.000
PLPP6	FIMP	psi-mi:“MI:0915”(physical association)	0.000
NSG1	FIMP	psi-mi:“MI:0915”(physical association)	0.000
MYADM	FIMP	psi-mi:“MI:0915”(physical association)	0.000
STATH	FIMP	psi-mi:“MI:0915”(physical association)	0.000
TMEM35A	FIMP	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): C16orf92 (Two-hybrid), C16orf92 (Two-hybrid), C16orf92 (Two-hybrid), C16orf92 (Two-hybrid), C16orf92 (Two-hybrid), NSG1 (Two-hybrid), MYADM (Two-hybrid), LRP10 (Two-hybrid), PPAPDC2 (Two-hybrid), PGA4 (Two-hybrid), B4GALT5 (Affinity Capture-MS), GOLM1 (Affinity Capture-MS), NDFIP1 (Affinity Capture-MS), APOE (Affinity Capture-MS), BIRC2 (Affinity Capture-MS)

ESM2 similar proteins: A0A0D1DMK2, A0A1B0GUV1, A8MUN3, A9G6D9, B8DP12, L7N648, O90299, P03294, P06791, P0C5K6, P0C854, P0DMW3, P15099, P16791, P16835, P25620, P34245, P40057, P53211, P69616, P69617, P75410, Q04612, Q07649, Q08419, Q32L37, Q3BSH4, Q494R0, Q53513, Q5YCU7, Q5YCU8, Q64747, Q64902, Q6J1A5, Q6J8G1, Q6Q572, Q6REU5, Q6UXP9, Q6ZS49, Q6ZUT4

Diamond homologs: E9Q9R3, Q96LL3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	1
Uncertain significance	20
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1268236	NM_031478.6(TLCD3B):c.234del (p.Gln79fs)	Pathogenic
1330201	GRCh37/hg19 16p11.2(chr16:29808153-30750270)x3	Pathogenic
625604	GRCh37/hg19 16p11.2(chr16:29595483-30199713)	Pathogenic
148545	GRCh38/hg38 16p11.2(chr16:29427948-30320693)x3	Likely pathogenic

SpliceAI

838 predictions. Top by Δscore:

Variant	Effect	Δscore
16:30025468:C:CC	acceptor_gain	1.0000
16:30025819:CAC:C	acceptor_gain	1.0000
16:30025820:ACC:A	acceptor_loss	1.0000
16:30025821:CCTGG:C	acceptor_loss	1.0000
16:30025823:T:C	acceptor_loss	1.0000
16:30026604:CTCAC:C	donor_loss	1.0000
16:30026607:A:AC	donor_gain	1.0000
16:30026607:A:T	donor_loss	1.0000
16:30026608:C:CC	donor_gain	1.0000
16:30026608:CCA:C	donor_gain	1.0000
16:30026839:AGTGT:A	acceptor_gain	1.0000
16:30026840:GTGT:G	acceptor_gain	1.0000
16:30026841:TGT:T	acceptor_gain	1.0000
16:30026841:TGTCT:T	acceptor_loss	1.0000
16:30026842:GT:G	acceptor_gain	1.0000
16:30026843:TCT:T	acceptor_loss	1.0000
16:30026844:C:CC	acceptor_gain	1.0000
16:30026844:C:CG	acceptor_loss	1.0000
16:30026845:T:A	acceptor_loss	1.0000
16:30025463:TTGTA:T	acceptor_gain	0.9900
16:30025464:TGTA:T	acceptor_gain	0.9900
16:30025465:GTA:G	acceptor_gain	0.9900
16:30025466:TA:T	acceptor_gain	0.9900
16:30025467:AC:A	acceptor_loss	0.9900
16:30025468:C:CA	acceptor_loss	0.9900
16:30025469:T:C	acceptor_loss	0.9900
16:30025724:A:AC	donor_gain	0.9900
16:30025725:C:CC	donor_gain	0.9900
16:30025781:A:C	acceptor_gain	0.9900
16:30025817:CACAC:C	acceptor_gain	0.9900

AlphaMissense

706 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:30023801:T:C	F69L	0.972
16:30023803:C:A	F69L	0.972
16:30023803:C:G	F69L	0.972
16:30023873:T:C	F93L	0.971
16:30023875:C:A	F93L	0.971
16:30023875:C:G	F93L	0.971
16:30023849:T:C	F85L	0.970
16:30023851:T:A	F85L	0.970
16:30023851:T:G	F85L	0.970
16:30023798:T:C	F68L	0.969
16:30023800:C:A	F68L	0.969
16:30023800:C:G	F68L	0.969
16:30023850:T:C	F85S	0.968
16:30023856:G:T	G87V	0.965
16:30023802:T:G	F69C	0.955
16:30023859:A:T	E88V	0.951
16:30023843:G:C	A83P	0.948
16:30023853:T:A	I86N	0.936
16:30023850:T:G	F85C	0.933
16:30023780:T:C	F62L	0.926
16:30023782:C:A	F62L	0.926
16:30023782:C:G	F62L	0.926
16:30023802:T:C	F69S	0.922
16:30023808:A:G	Y71C	0.922
16:30024034:G:C	G109R	0.921
16:30023859:A:C	E88A	0.919
16:30023799:T:G	F68C	0.913
16:30023874:T:G	F93C	0.911
16:30023860:G:C	E88D	0.908
16:30023860:G:T	E88D	0.908

dbSNP variants (sampled 300 via entrez): RS1000241646 (16:30021255 G>A,T), RS1000318863 (16:30024907 C>T), RS1001399239 (16:30023561 C>G,T), RS1002069923 (16:30021349 C>G,T), RS1002462729 (16:30024471 C>T), RS1002871038 (16:30028125 A>G), RS1003154661 (16:30022934 C>T), RS1003741914 (16:30024308 T>C), RS1003802810 (16:30024966 G>A,C), RS1003870789 (16:30027515 C>A,T), RS1004092169 (16:30021678 C>G,T), RS1004465261 (16:30021881 A>C,G), RS1005251294 (16:30024611 T>C), RS1005737190 (16:30023115 C>G), RS1006320799 (16:30025903 G>A)

Disease associations

OMIM: gene MIM:618911 | disease phenotypes: MIM:611881, MIM:615401, MIM:128200, MIM:619531, MIM:614671

GenCC curated gene-disease

Mondo (7): glycogen storage disease due to aldolase A deficiency (MONDO:0012747), severe combined immunodeficiency due to CORO1A deficiency (MONDO:0014168), episodic kinesigenic dyskinesia (MONDO:0044202), cone-rod dystrophy 22 (MONDO:0030440), chromosome 16p11.2 duplication syndrome (MONDO:0013847), neutropenia (MONDO:0001475), lymphopenia (MONDO:0003783)

Orphanet (4): Severe combined immunodeficiency due to CORO1A deficiency (Orphanet:228003), Glycogen storage disease due to aldolase A deficiency (Orphanet:57), Paroxysmal kinesigenic dyskinesia (Orphanet:98809), Proximal 16p11.2 microduplication syndrome (Orphanet:370079)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0001875	Decreased total neutrophil count
HP:0001888	Decreased total lymphocyte count

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST002539_82	Schizophrenia	5.000000e-11
GCST004521_236	Autism spectrum disorder or schizophrenia	4.000000e-10
GCST006803_23	Schizophrenia	6.000000e-13
GCST007293_15	Body fat distribution (arm fat ratio)	6.000000e-06
GCST007293_81	Body fat distribution (arm fat ratio)	4.000000e-08
GCST007611_22	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	7.000000e-09
GCST010703_269	Brain morphology (MOSTest)	4.000000e-13

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004341	body fat distribution
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D008231	Lymphopenia	C15.378.243.750.605; C15.378.553.546.605; C20.673.627
D009503	Neutropenia	C15.378.243.750.184.564; C15.378.553.546.184.564
C562718	Glycogen Storage Disease XII (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

6 total (human), top 6 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Benzo(a)pyrene	affects methylation	1
Plant Extracts	decreases expression, affects cotreatment	1
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

200 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00030758	PHASE4	UNKNOWN	Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
NCT00125723	PHASE4	COMPLETED	FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
NCT00194857	PHASE4	TERMINATED	Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
NCT00257790	PHASE4	COMPLETED	The Tobramycin Study
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00686543	PHASE4	COMPLETED	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
NCT01086878	PHASE4	COMPLETED	Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
NCT01114165	PHASE4	COMPLETED	Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients
NCT01135589	PHASE4	UNKNOWN	Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation
NCT01571518	PHASE4	UNKNOWN	Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy
NCT02621905	PHASE4	COMPLETED	Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
NCT02967341	PHASE4	UNKNOWN	Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients
NCT04009941	PHASE4	COMPLETED	Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
NCT04904614	PHASE4	COMPLETED	Letermovir Use in Heart Transplant Recipients
NCT05626530	PHASE4	RECRUITING	Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
NCT06145321	PHASE4	ACTIVE_NOT_RECRUITING	Continuous Versus Bolus Administration of G-CSF in Children With Cancer
NCT00001338	PHASE3	COMPLETED	A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
NCT00001646	PHASE3	COMPLETED	Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
NCT00002658	PHASE3	UNKNOWN	Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
NCT00002719	PHASE3	COMPLETED	Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
NCT00003739	PHASE3	COMPLETED	Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
NCT00020865	PHASE3	UNKNOWN	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
NCT00035594	PHASE3	COMPLETED	Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
NCT00044486	PHASE3	COMPLETED	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
NCT00107081	PHASE3	TERMINATED	Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting
NCT00445497	PHASE3	UNKNOWN	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
NCT00529282	PHASE3	TERMINATED	A Study of Ceftobiprole in Patients With Fever and Neutropenia.
NCT00627393	PHASE3	COMPLETED	Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
NCT00770172	PHASE3	COMPLETED	G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
NCT00784368	PHASE3	COMPLETED	A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
NCT00806351	PHASE3	TERMINATED	An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
NCT00911170	PHASE3	COMPLETED	PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
NCT01307579	PHASE3	COMPLETED	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
NCT01371656	PHASE3	COMPLETED	Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
NCT01560195	PHASE3	UNKNOWN	A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
NCT01611051	PHASE3	COMPLETED	A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
NCT02238873	PHASE3	UNKNOWN	Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
NCT02414581	PHASE3	COMPLETED	Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7%
NCT02643420	PHASE3	COMPLETED	SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
NCT02872103	PHASE3	COMPLETED	Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy